Research
- Last Updated On :
RESEARCH
A. Funded Research
Completed
1. Advanced Centre for Liver Disease (different projects in liver diseases)
- Acute Liver Failure in Pregnancy. Is the prognosis really worse?
- Anti tuberculosis therapy induced acute liver failure.
- Ammonia kinetics in acute liver failure.
- An insight into Pathogenesis of “Non-alcoholic fatty liver disease in Indian Patients”
Principal Investigator : Dr. S.K. Acharya
Funding Agency : ICMR – Advanced Centre for Liver Disease
Total : Rs. 2 crore
Duration : 2004-10
1.Is chronic pancreatitis a pre-malignant disease?
Chief Investigator : Pramod Garg
Funding Agency : ICMR,
Total : Rs. 14 lacs,
Duration: : 2007-10
- 2.A pilot study to estimate community prevalence of Celiac Disease.
Name of Principal Investigator : Dr. Govind K. Makharia
Funding agency : Indian Council of Medical Research
Total funding : Rs. 17,11,988/-
Duration : 2008-10
- 3.Efficacy and Safety of Mesalamine Delayed-Release Tablets (1.2g), Par Pharmaceutical (Test Drug) in the treatment of active mild to moderate ulcerative colitis: A Double Blinded, Double Dummy, Multicentre Randomized Phase III, Comparison with Placebo and Lialda (1.2g) Mesalamine Delayed-Release Tablets, Shire US Inc (Reference Drug) – 292-07.
Name of Principal Investigator : Dr. Govind K. Makharia
Funding agency : Par Pharmaceutical Companies, Inc.
Total funding : Rs. 4,35,699/-
Duration : 2008-09
- 4.A multicentre (Country wide) prospective data collection of patients with Inflammatory Bowel Disease under Indian Society of Gastroenterology task force on Inflammatory Bowel Disease.
Name of Principal Investigator : Dr. Govind K. Makharia
Funding agency : Indian Society of Gastroenterology TF on IBD
Total funding : Rs. 1,69,724/-
Duration : 2008-10
- 5. A Phase2/3 Multicentre, Randomized, Placebo-controlled, Double-blind study to Evaluate the safety and efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis.
Name of Principal Investigator : Dr. Govind K. Makharia
Funding agency : Centocor
Total funding : Rs. 13,56,380/-
Duration : 2008-11
Ongoing
1.Identification of biomarker (s) for differentiation of Crohn’s disease from
intestinal tuberculosis using proteomic.
Name of investigator : Dr.S.K.Acharya
Funding agency : DBT
Total funding : 43 Lakhs
Duration : 2008-11
2.An open level responses adaptitative study of Telbivudine in adults with HBeAg
compensated chronic hepatitis B.
Name of investigator : Dr.S.K.Acharya
Funding agency : Novartis
Total funding : 11,11000 (Eleven lakh and eleven thousand only)
Duration : 2008-13
3.An open level responses adptitative study of Telbivudine in adults with HBeAg negative compensated chronic hepatitis B.
Name of investigator : Dr.S.K.Acharya
Funding agency : Novartis
Total funding : Support of drugs & investigation
Duration : 2008-11
4. Advanced Centre for Liver Disease (Institute & different projects in liver diseases)
a)Hepatic venous – outflow tract obstruction: etiology and results of angioplasty.
b)Probiotics for spontaneous Bacterial Peritonitis.
c)Neutrophillic function studies in acute liver failure.
d)Randomised control trial of percutaneous Acetic Acid and Radio frequency ablation in HCC.
e)Sepsis in acute liver failure.
f)Seizures in acute liver failure.
Name of investigator : Dr.S.K.Acharya
Funding agency : ICMR (Advanced Centre)
Total funding : 2 Crores
Duration : 2005-10 (still continue taken over by AIIMS)
5.A Multicentric randomized controlled clinical trial of adefovir, adefovir + Lamivudine and combination of Adefovir and Glycyrrhizin in HBV related decompensated cirrhosis
Name of Investigator : Dr. S.K. Acharya
Funding Agency : ICMR
Total funding : Rs. 18, 47,000
Duration : 2007-12
6.Natural Course of Immunotolent Patients with chronic HBV infectioin
Name of Investigator : Dr. S.K. Acharya
Funding Agency : MSD (Fulford India)
Total funding : 18,79,750
Duration : 2010-13
7. Health Related quality of life in patient with chronic liver disease and effect of probiotics in the treatment of MHE and health related quality of life
Name of the investigator : Dr. Y.K.Joshi
Funding Agency : ICMR
Total funding : Rs. 27 lakhs
Duration : 2009-11
8.“Efficacy of daily iron folic acid supplementation in correction of iron deficiency anemia in children aged 3-5 years.
Name of PI : Dr. Umesh Kapil
Funding agency : Indian Council of Medical Research
Total funding : Rs. 14,46,263
Duration of Project : 2009-11
9.Resolution of Bitot’s Sports after Administration of Mega-dose of Vitamin A in a cohort of children in 1-5 years of age with Bitot’s sport
Name of PI : Dr. Umesh Kapil
Funding agency : Indian Council of Medical Research
Total funding : Rs. 16,58,381
Duration of Project : 2010-12
10.“Validity of Spot Testing Kits in the Assessment of Iodine Content of Salt-A Multicentric Study”
Name of PI : Dr. Umesh Kapil
Funding agency : MBI Kits
Total funding : Rs. 4,98,520
Duration of Project : 2010-12
11. A Study of Mutational and Histopathological risk factors for Gallbladder Cancer in Patients with Gallstones.
Name of PI : Pramod Garg.
Funding Agency : DBT
Total : Rs. 32 lacs,
Duration : 2008-11
12.“Role of TNF-α in the pathogenesis of experimental acute pancreatitis and the
effect of anti-TNF-α therapy in attenuating the severity of pancreatitis and in
the subsequent regeneration of the pancreas”.
Name of PI : Pramod Garg.
Funding Agency : ICMR,
Total : Rs. 29 lacs,
Duration : 2009-12
13. A multi-centric study on treatment of abdominal tuberculosis (intestinal or peritoneal): A randomized controlled trial to compare the 6 months of Cat-I treatment with 9 months of Cat-I treatment (extension for 3 months) in abdominal tuberculosis under the Revised National Tuberculosis Control Program.
Name of Principal Investigator : Dr. Govind K. Makharia
Funding agency : Ministry of Health & Family welfare
Total funding : Rs. 57,40,071/-
Duration : 2007-11
- 14.Detection of Mycobacterial pathogens in patients with Crohn’s Disease.
Name of Principal Investigator : Dr. Govind K. Makharia
Funding agency : Department of Biotechnology
Total funding : Rs. 35,26,000/-
Duration : 2007-2011
- 15. Characterization of tight Junction proteins in patients with Crohn’s Disease and Celiac Disease.
Name of Principal Investigator : Dr. Govind K. Makharia
Funding agency : Department of Science & Technology
Total funding : Rs. 24,10,400/-
Duration : 2009-2012
- 16. Protocol for Correlating Enteropathic Severity and Small Intestinal CYP3A4 Activity in Patients with Celiac Disease.
Name of Principal Investigator : Dr. Govind K. Makharia
Funding agency : Flamentera, AG (Switzerland)
Total funding : Rs. 11,00,000/-
Duration : 2010-2011
- 17.Pathophysiology of paracellular permeability and tight junctions in the first degree relatives of patients with celiac disease.
Name of Principal Investigator : Dr. Govind K. Makharia
Funding agency : Department of Biotechnology
Total funding : Rs. 43,82,000/-
Duration : 2011-2014
- 18.Small intestinal and whole gut metagenome in patients with celiac disease, their first degree relatives and controls.
Name of Principal Investigator : Dr. Govind K. Makharia
Funding agency : Department of Biotechnology
Total funding : Rs. 39,47,600/-
Duration : 2011-2013
19. "Zoonotic potential of Mycobacterium avium paratuberculosis (MAP) in human Ulcero-constrictive Ileocaecal Disease" .
Name of the PI : Dr. Vineet Ahuja
Funding Agency : ICMR
Amount : Rs 57 lakhs.
Duration : 2011-14 ;
20.A Phase 3, Randomised, Placebo-Controlled, Blinded, Multicentre Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis.
Name of the PI : Dr. Vineet Ahuja
Funding Agency : Millenium Pharma, Boston, MA.
Amount : Rs 5 lakhs approx.
Duration : 2009-12
21.A Phase 3, Randomized, Placebo Controlled, Blinded, Multicenter, Multiple Dose Study to Determine the Efficacy and Safety of MLN0002 for the Induction & Maintenance of Clinical Response and Remission in Patients with Active Crohn’s Disease.
Name of the PI : Dr. Vineet Ahuja
Funding Agency : Millenium Pharma, Boston, MA
Amount : Rs 5 lakhs approx
Duration : 2009-12
B. Departmental Research
Completed:
1. Acute Viral hepatitis in Diabetics: Evaluation of Natural course
2. Three month treatment of chronic hepatitis – C with Interferon a 2b and Ribavirine.
3. Hematological Abnormalities in Cirrhosis of liver
4. Prevalence of irritable bowel syndrome in community
5. Effect of addition of short course of prednisolone to gluten free diet and gluten free diet alone in the recovery of clinical, histological and immunological features in naive adult patients with celiac disease: A pilot randomized controlled trial.
6.Long-Term Pain Relief with Optimized Medical Therapy Including Antioxidants in Chronic Pancreatitis.
7.Association of SPINK1 Gene Mutation and CFTR Gene Polymorphisms in Patients with Pancreas Divisum Presenting with Idiopathic Pancreatitis.
8.Idiopathic Chronic Pancreatitis in India: Phenotypic Characterization and Strong Genetic Susceptibility due to SPINK1 and CFTR Gene
Ongoing:
1.HBeAg –ve chronic hepatitis B Magnitude, Viral & host characteristics.
2. Immunotolerant chronic HBV infection: Natural course
3. Role of HVPG in Portal hypertension
4.Prevalence of celiac disease in irritable bowel syndrome and dyspepsia (DM thesis).
5.Plasma citrulline as a marker estimation of enterocytes mass in patients with celiac disease and other malabsorption syndromes.
6.Prevalence of celiac disease in first degree relatives of patients with celiac disease.
7.Prevalence of celiac disease in patients with nutritional anemia (DM thesis).
8. Familial prevalence amongst first and second degree relatives of patients with celiac disease.
9. Endoscopic biliary drainage versus conservative treatment for patients with inoperable cancer of the gallbladder with obstructive jaundice: A randomized controlled trial.
10.Role of MRI in the evaluation of infected pancreatic necrosis for conservative treatment including non-surgical drainage.
11.Comparison of Phenotype and Genotype of Young Patients with Chronic Pancreatitis from Different Geographical and Ethnic Background of the World: Implications for Etiopathogenesis.
12.Factors predictive of relapse in patients with Ulcerative colitis in remission : A long term follow up study.
13.Differentiating Intestinal tuberculosis from Crohn’s Disease : Biomarker search.
14.Mucosal healing in IBD : Is it a relevant end point ?
15.Longitudinal cohort of Ulcerative colitis : Long term follow up.
16.Dynamics of differential T regulatory cell expression in Inflammatory Bowel
disease and Intestinal tuberculosis.
C. Collaborative Research Projects
Completed
1. Attitude towards colorectal cancer (Collaborative study, Asia Pacific clolorectal Cancer Study Group).
2. Prevalence of celiac disease in autoimmune diseases (autoimmune thyroid diseases, rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis, juvenile arthritis). (with Dept of Medicine and Endocrinology).
3. Effect of treatment (laparoscopic cardiomyotomy and pneumatic dilatation) on structural and functional abnormalities of the lungs in achalasia (With Dept of Surgery, MS thesis).
4. Genetic study of Giardia lamblia (With Dept of Microbiology, MD thesis).
5. Prevalence and significance of celiac disease in patients with type-I diabetes. (Endocrinology).
6. Expression of tight junction markers in colonic Crohn’s disease, ulcerative colitis and intestinal tuberculosis.
7. A multicenter (Country wide) prospective data collection of patients with inflammatory bowel disease under Indian Society of Gastroenterology Task Force on Inflammatory Bowel Disease.
8. A comparison of colonoscopy and PET-CT colonography for evaluation of extent of disease in patients with Ulcerative Colitis: A pilot study.
9. Evaluation of psychiatric and somatic co-morbidities in patients with irritable bowel syndrome. (With Department of Psychiatry).
10. Comparative evaluation of PET CT scan and EUS in patients with suspected pancreatic malignancy. Collaborative departments: Department of Nuclear Medicine.
Ongoing
1. Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection.
2. HBV mutants among patients with acute and chronic liver disease.
3. Cellular and humoral immunity studies among patients with acute hepatitis E virus infection.
4. HCV quantitation assay and HEV quantitation assay and HEV quantitation assay development and their relevance.
5. A randomized trial of endoscopic versus laparoscopic removal of common bile duct stones in patients with gallstones and CBD stones. Collaborative departments: Department of Surgery.
6. Randomised trial of endoscopic stenting versus cholecystojejunostomy in patients with peri-ampullary cancer with obstructive jaundice. Collaborative departments: Department of GI Surgery.
7. Role of EUS is assessing resectability of periampullary tumors: comparison with diagnostic laparoscopy. Department of Surgery.
8. A randomized trial of endoscopic versus laparoscopic drainage of pancreatic pseudocysts. Collaborative departments: Department of Surgery.
9. TPMT polymorphisms in IBD.
10. Prevalence and clinicopathological correlation of chronic gastritis in a high.altitude area in India
11. Response to antitubercular therapy in patients with Crohn’s Disease : Predictive factors
12. A study for the search of biomarker for celiac disease using proteomics
13. Detection of metabolic signature of patients with celiac disease using in-vitro 1H magnetic resonance spectroscopy (With department of NMR).
14. Detection, identification and molecular characterization of Intestinal coccidia and Microsporidia in patients with chronic diarrhea and malabsorption syndrome (With Department of Microbiology, PhD thesis).
15. Effect of addition of short course of prednisolone to gluten free diet and gluten free diet alone in the recovery of clinical, histological and immunological features in naive adult patients with celiac disease: A pilot randomized controlled trial.
16. Seroprevalence of celiac disease in healthy blood donors,. (With Blood Bank).
17. Basic constitution (Prakriti) analysis of patients with various stages of Non alchoholic fatty liver disease (NAFLD), chronic hepatitis B (CHB) and Celiac disease.
